Maynard Um
-
-
-
-
-
-
-
Sonnet BioTherapeutics (SONN) Successfully Completes First Safety Review of SON-1010 in Combination with Trabectedin
-
-
-
-
-
-
-
Sonnet BioTherapeutics (SONN) Announces $3.9 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
-
-
-
-
-
-
-
Sonnet BioTherapeutics (SONN) Regains Nasdaq Compliance
-
-
-
-
-
-
-
Sonnet BioTherapeutics (SONN) Receives $3.4M From Warrants Exercise
341,965 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

